Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Muenter, M. D.
Right arrow Articles by McManis, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muenter, M. D.
Right arrow Articles by McManis, P.
NEUROLOGY 1988;38:1541
© 1988 American Academy of Neurology

PHNO [(+)-4-propyl-9-hydroxynaphthoxazine]

A new and effective anti-Parkinson's disease agent

Manfred D. Muenter, MD, J. Eric Ahlskog, PhD, MD, Gaye Bell, RN and Philip McManis, MB, BS, FRACP

Mayo Clinic Scottsdale (Dr. Muenter), Scottsdale, AZ; and the Department of Neurology (Drs. Ahlskog and McManis and Mrs. Bell), Mayo Clinic and Mayo Foundation, Rochester, MN.

PHNO [(+)-4-propyl-9-hydroxynaphthoxazine] is a chemically novel and highly potent dopamine (D2) receptor agonist without D1 activity. It had significant antiparkinsonism effects when used as open-label monotherapy in ten patients who were Hoehn and Yahr stage 2 or 3. The standard formulation of PHNO produced a 3- to 4-hour therapeutic effect in most patients; the response to the time-release formulation lasted up to 10 hours. Side effects were similar to those of other dopamine agonists but dyskinesia was seen in only one patient.

Address correspondence and reprint requests to Dr. Muenter, Mayo Clinic Scottsdale, 13400 Shea Boulevard, Scottsdale, AZ 85259.

Supported by funding from Merck Sharp & Dohme Research Laboratories, West Point, PA, and NIH grant RR485 (Mayo Clinical Research Center).

Received December 10, 1987. Accepted for publication in final form March 16, 1988.




This article has been cited by other articles:


Home page
 Arch NeurolHome page
J. E. Ahlskog, M. D. Muenter, P. A. Bailey, and P. M. Stevens
Dopamine Agonist Treatment of Fluctuating Parkinsonism: D-2 (Controlled-Release MK-458) vs Combined D-1 and D-2 (Pergolide)
Arch Neurol, May 1, 1992; 49(5): 560 - 568.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by AAN Enterprises, Inc.